M-EDG's
Florida-Israel
Biomedical Initiative U.S. Commercialization for Israel's Biomedical Products
The FL-IBI provides a very well-suited marketing and distribution vehicle for the U.S. commercialization of Israel’s biomedical devices and products.* The main benefits to the Israeli biomedical companies seeking U.S. distribution relates to M-EDG’s Equity-based Business Model™, which provides significant equity/ownership rather than simply a royalty under a conventional licensing agreement.
The main benefits to the
Israeli companies and their owners are:
-
Significantly greater participation in successful U.S. commercialization
-
From 20 to 30 times greater ROI for equity interests in Israeli biomedical companies
-
Post-commercialization Israeli majority-ownership potential
-
Increased U.S. recognition of Israel’s preeminent biomedical product development expertise.
*
NOTE: In order to
successfully commercialize medical products in the U.S. healthcare
industry, it is vital to successfully manage over a dozen functional
areas in addition to marketing and distribution and to have had
significant experience and responsibility in managing each of these
typically interrelated functional areas. (For a listing of these
dozen areas, note the "What
We Do" page of this website.) The senior management
of M-EDG, the parent of the Florida--Israel
Biomedical Initiative, possesses well over 200 man-years of
hands-on and senior management responsibility for these dozen-plus
functional areas.
CLICK HERE
to read a list of
incredible scientific and technology breakthroughs
that were developed by and in the nation of Israel.
Israel
101
is produced by Stand
With Us, and provides an excellent introduction and historical
perspective to many of the issues facing Israel and the world.
NOTE: Clicking
the Israel 101 link will open a new window. M-EDG
is not responsible for the content of external websites.
